Pipeline Watch: Six Phase III Trial Starts Plus 19 New Approvals
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Merck’s KEYNOTE-756 Hits One Primary Endpoint, But Don’t Pop The Champagne Yet
The study, in ER+/HER2- breast cancer, met the pCR co-primary endpoint. Merck previously tried without success to win accelerated approval for Keytruda in TNBC using pCR as a surrogate for EFS.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.